The Protocol Review and Monitoring System provides a centralized framework for initial evaluation and prioritization of more than 160 new studies per year and ongoing monitoring of more than 200 clinical research studies in collaboration with our Institutional Review Board, regulatory agencies, and sponsors. With institutional support, major initiatives were undertaken in key areas during the current grant cycle: 1) Data and Safety Monitonng (DSM): Our Institutional master DSM Plan (DSMP) was written, reviewed, implemented, NCI-approved (JAN-2002), and amended for DCP-CCOP approval (FEB-2004). The DSMP included creation of a local Phase l-ll Protocol Monitoring Committee (Burtness, formerly R. Cohen) to provide oversight for investigator-initiated studies that do not require a full or independent DSMB. 2) Scientific Review: Research Review Committee chair transitioned from the G. Hudes, who still serves as a reviewer, to Schilder, an independent investigator and long-term member of the committee. 3) Quality Assurance: Expansion of the QA program with growth of the Investigator Initiated Program at extramural sites. Continued source documentation for eligibility criteria and 100% internal auditing of protocol eligibility. Integration of expanded QA procedures with the master DSMP. 4) Regulatory Support: Staff resources expanded to manage increased study volume, amendments, safety reports, adverse event reports, HIPAA documentation, sponsor communications, certifications, NCl-CTSU reporting, and global revisions to informed consent documents. 5) Informatics: Enhanced automated reports to support continuing reviews. Specialized database tools for efficient management and distribution of more than 5000 annual safety reports.

Public Health Relevance

A particularly important function for centers involved in clinical research is a mechanism for assuring adequate internal oversight of the scientific aspects of all the cancer clinical trials in the institution or institutions that formally comprise the center. This function is complementary to that of an Institutional Review Board (IRB), which focuses on the protection of human subjects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475350
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$63,573
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580

Showing the most recent 10 out of 1280 publications